New York (AFP) – Pfizer has already started working on a version of its Covid-19 vaccine specifically targeting the Omicron variant in case the current inoculation is not effective against the new strain, the US drugmaker’s CEO Albert Bourla said Monday. Bourla told CNBC that his company on Friday began testing the current vaccine against the Omicron variant, which was first reported in South Africa and reignited fears of a global wave of Covid-19 infections. “I don’t think the result will be the vaccines don’t protect,” Bourla said.  But the testing could show that existing shots “protect les…

Read More